Manogram.org of Admetech Foundation
brochure 1

More men get prostate cancer than women get breast cancer. Over 230,000 men were stricken, 30,000 died and over 1.5 million had biopsies in 2004. And yet, men do not have accurate diagnostic tools for early detection and treatment. According to a recent study by the National Cancer Institute, PSA blood tests that screen for prostate cancer result in false-negative reassurances and numerous false-positive alarms. Some 15% of men with normal PSA levels still have prostate cancer. Even when PSA levels are abnormal, some 88% of men end up not having prostate cancer but undergoing unnecessary biopsies. Developing new imaging technologies is critical for accurate early detection, when prostate cancer can be treated with minimal discomfort, complications and costs. It's time to end the fear, pain and suffering caused by prostate cancer. Isn't it time for a “Manogram™” — life-saving imaging for men?

brochure 2

More men get prostate cancer than women get breast cancer. Over 230,000 men were stricken, 30,000 died and over 1.5 million had biopsies in 2004. And yet, men do not have accurate diagnostic tools for early detection and treatment. According to a recent study by the National Cancer Institute, PSA blood tests that screen for prostate cancer result in false-negative reassurances and numerous false-positive alarms. Some 15% of men with normal PSA levels still have prostate cancer. Even when PSA levels are abnormal, some 88% of men end up not having prostate cancer but undergoing unnecessary biopsies. Developing new imaging technologies is critical for accurate early detection, when prostate cancer can be treated with minimal discomfort, complications and costs. It's time to end the fear, pain and suffering caused by prostate cancer. Isn't it time for a “Manogram™” — life-saving imaging for men?

brochure 3

Prostate cancer has reached epidemic proportions. It strikes 1 in 6 men and has become the second leading cause of cancer deaths in men. Yet men do not have accurate and affordable imaging to guide early detection, biopsy and treatment. Without such imaging, patient care may be blind.Worse yet, treatment is costly and leaves up to 80% of patients impotent and incontinent. New imaging technologies will arm physicians with accurate visualization tools critical for early detection and informed clinical decisions. Ultimately, image-guided, minimally invasive treatment will shift prostate cancer care to outpatient clinics, with minimal discomfort, complications and costs. The AdMeTech Foundation, a non-profit organization committed to fostering advancements in imaging technologies, is committed to ending the fear, pain, suffering and costs prostate cancer causes men, their families and our society.

brochure 4

More men get prostate cancer than women get breast cancer. Over 230,000 men were stricken, 30,000 died and over 1.5 million had biopsies in 2004. And yet, men do not have accurate diagnostic tools for early detection and treatment. According to a recent study by the National Cancer Institute, PSA blood tests that screen for prostate cancer result in false-negative reassurances and numerous false-positive alarms. Some 15% of men with normal PSA levels still have prostate cancer. Even when PSA levels are abnormal, some 88% of men end up not having prostate cancer but undergoing unnecessary biopsies. Developing new imaging technologies is critical for accurate early detection, when prostate cancer can be treated with minimal discomfort, complications and costs. It's time to end the fear, pain and suffering caused by prostate cancer. Isn't it time for a “Manogram™” — life-saving imaging for men?

brochure 5

Without accurate and affordable imaging technologies, the prostate is one of the last human organs where detection and treatment methods are essentially blind. There are no accurate, affordable imaging tools for early detection, guidance of biopsy and treatment. Treatment results in many complications, including impotence and incontinence in up to 80% of patients. But there is hope. New imaging technologies will arm physicians with accurate visualization tools critical for early detection and informed clinical decisions. Ultimately, image-guided, minimally invasive treatment will shift prostate cancer care to ambulatory clinics, with minimal discomfort, complications and costs. At the non-profit AdMeTech Foundation, we are committed to the advancement of imaging technologies for prostate cancer care, embracing solutions that can put an end to the pain and suffering prostate cancer causes men and their families.

brochure 6

More men get prostate cancer than women get breast cancer. Over 230,000 men were stricken, 30,000 died and over 1.5 million had biopsies in 2004. And yet, men do not have accurate diagnostic tools for early detection and treatment. According to a recent study by the National Cancer Institute, PSA blood tests that screen for prostate cancer result in false-negative reassurances and numerous false-positive alarms. Some 15% of men with normal PSA levels still have prostate cancer. Even when PSA levels are abnormal, some 88% of men end up not having prostate cancer but undergoing unnecessary biopsies. Developing new imaging technologies is critical for accurate early detection, when prostate cancer can be treated with minimal discomfort, complications and costs. It's time to end the fear, pain and suffering caused by prostate cancer. Isn't it time for a “Manogram™” — life-saving imaging for men?

The Promise of Imaging Technology
for Prostate Cancer Diagnosis
and Treatment

The Promise of Imaging Technology for Prostate Cancer Diagnosis and Treatment
Andrew von Eschenbach
FDA Commissioner
,
former Director of National Cancer Institute
View the video clip of the interview

image of prosty

 

Meet
Prosty the Spokesgland©, champion of the effort to develop a Manogram™

Download the educational public service brochures part of the educational services created to build awareness and demand for Manogram™:
brochure 1 brochure 2 brochure 3 brochure 4 brochure 5 brochure 6